UroGen Pharma Ltd (URGN) — Cash Flow-to-Debt Ratio
UroGen Pharma Ltd (URGN) has a Cash Flow-to-Debt Ratio of -0.12x as of March 2026, meaning its operating cash flow of $-45.32 Million could theoretically repay 0% of its total liabilities ($377.94 Million) in one year. Explore URGN strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
UroGen Pharma Ltd Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for UroGen Pharma Ltd across 13 annual periods. Also explore UroGen Pharma Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for UroGen Pharma Ltd (2013–2025)
Year-by-year debt coverage analysis for UroGen Pharma Ltd. For market capitalisation and broader financial context, see market cap of UroGen Pharma Ltd.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.53x | $-162.44 Million | $305.93 Million | ▼ -61.6% |
| 2024 | -0.33x | $-96.77 Million | $294.51 Million | ▼ -4.8% |
| 2023 | -0.31x | $-76.38 Million | $243.52 Million | ▲ +19.4% |
| 2022 | -0.39x | $-87.56 Million | $224.98 Million | ▲ +49.0% |
| 2021 | -0.76x | $-84.89 Million | $111.33 Million | ▲ +81.5% |
| 2020 | -4.13x | $-105.89 Million | $25.65 Million | ▼ -28.4% |
| 2019 | -3.22x | $-71.02 Million | $22.09 Million | ▼ -16.0% |
| 2018 | -2.77x | $-37.33 Million | $13.46 Million | ▼ -103.8% |
| 2017 | -1.36x | $-9.57 Million | $7.04 Million | ▼ -319.2% |
| 2016 | 0.62x | $4.19 Million | $6.75 Million | ▲ +119.4% |
| 2015 | -3.21x | $-7.17 Million | $2.24 Million | ▲ +30.6% |
| 2014 | -4.62x | $-4.12 Million | $891.00K | ▲ +12.5% |
| 2013 | -5.28x | $-2.56 Million | $484.00K | — |